As women continue using Medroxyprogesterone Acetate Injectable Suspension, USP, fewer experience irregular bleeding and more experience amenorrhea. Also tell them about any supplements you take.
Get Active This Spring! Medroxyprogesterone Rating User Reviews 4.
If an anaphylactic reaction occurs appropriate therapy should be instituted. The mean decrease in BMD at weeks was more pronounced at total hip For this reason, women with diabetes should carefully monitor their blood glucose while receiving medroxyprogesterone acetate.
Using an unextracted radioimmunoassay procedure for the assay of Medroxyprogesterone Acetate in serum, the apparent half-life for Medroxyprogesterone Acetate following IM administration of Medroxyprogesterone Acetate Injectable Suspension, USP is approximately 50 days.
This medication has been associated with blood clots developing in the bloodstream. Depot medroxyprogesterone Depo-Provera and risk of breast cancer. Women who use medroxyprogesterone acetate injectable suspension may lose significant bone mineral density.
It is very important that this medication be used exactly as prescribed by the doctor. Although MPA Injectable Suspension, USP should not be used during pregnancy, there appears to be little or no increased risk of birth defects in women who have inadvertently been exposed to MPA injections in early pregnancy.
Use of medroxyprogesterone acetate injectable suspension reduces serum estrogen levels and is associated with significant loss of bone mineral density BMD as bone metabolism accommodates to a lower estrogen level. Women who continued for 6 years gained an average total of If examination reveals papilledema or retinal vascular lesions, medication should not be readministered.
MPA Injectable Suspension, USP should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur. Aminoglutethimide administered concomitantly with the Medroxyprogesterone Acetate Injectable Suspension, USP may significantly depress the serum concentrations of medroxyprogesterone acetate.
Indications and Usage for Medroxyprogesterone Injection
The effectiveness of Medroxyprogesterone Acetate Injectable Suspension, USP depends only on the patient returning every 3 months 13 weeks for her next injection. Patient labeling is included with each single-dose vial and prefilled syringe of Medroxyprogesterone Acetate Injectable Suspension, USP to help describe its characteristics to the patient. Because progestational drugs may cause some degree of fluid retention, conditions that might be influenced by this condition, such as epilepsy, migraine, asthma, and cardiac or renal dysfunction, require careful observation.
A study to assess the reversibility of loss of BMD in adolescents is ongoing. In general, adolescents increase bone density during the period of growth following menarche, as seen in the untreated cohort. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here.
You may experience a weight gain while you are using medroxyprogesterone acetate injectable suspension.
If abnormal bleeding persists or is severe, appropriate investigation should be instituted to rule out the possibility of organic pathology, and appropriate treatment should be instituted when necessary. If more than 14 weeks pass between SC injections, a pregnancy test should be done to rule out pregnancy before any further treatment with medroxyprogesterone.
The National Cancer Institute 8 reports an average annual incidence rate for breast cancer for US women, all races, age 30 to 34 years of Other than concerns about loss of BMD, the safety and effectiveness are expected to be the same for postmenarchal adolescents and adult women.